Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.7% Higher – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price rose 6.7% during trading on Monday . The stock traded as high as $15.90 and last traded at $13.89. Approximately 1,577,758 shares traded hands during mid-day trading, an increase of 162% from the average daily volume of 602,501 shares. The stock had previously closed at $13.02.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a market cap of $25.18 million, a P/E ratio of 0.00 and a beta of 2.23. The company has a 50 day moving average price of $21.24 and a 200-day moving average price of $20.57.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $40,000. Two Sigma Investments LP acquired a new position in Tonix Pharmaceuticals in the 4th quarter worth about $66,000. PFG Investments LLC bought a new position in Tonix Pharmaceuticals in the fourth quarter valued at about $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $526,000. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.